{"brief_title": "A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients", "brief_summary": "This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.", "condition": ["Kidney Transplantation"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Corticosteroids", "Neoral", "Neoral", "Zenapax", "mycophenolate mofetil [CellCept]"], "description": ["As prescribed", "Low dose (target trough level 50-100ng/mL)", "Standard dose (target trough level 150-300ng/mL)", "2mg/kg iv first dose, then 1mg/kg every 2 weeks", "1g po bid"], "arm_group_label": ["1", "2", "3", "1", "2", "3", "1", "2", "1", "2", "3"], "criteria": "Inclusion Criteria: - adult patients greater than 18 years of age - recipients of primary kidney transplant - single-organ recipients (kidney only) Exclusion Criteria: - previous treatment with Zenapax - history of malignancy (except localized skin cancer)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Daclizumab", "Mycophenolate mofetil", "Cyclosporine", "Cyclosporins", "Mycophenolic Acid"], "id": "NCT00048152"}